We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Soy Fiber Improves Weight Loss and Lipid Profile

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01802840
First Posted: March 1, 2013
Last Update Posted: March 1, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Xiaojie Hu, Zhejiang University
  Purpose
The aim of this study is to examine the effects of soy fiber on body weight, body composition and blood lipids in overweight and obese participants.

Condition Intervention
Obesity Overweight Weight Loss Dietary Supplement: biscuits supplemented with soy fiber

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Soy Fiber Improves Weight Loss And Lipid Profile In Overweight And Obese Adults: A Randomized Controlled Trial

Resource links provided by NLM:


Further study details as provided by Xiaojie Hu, Zhejiang University:

Primary Outcome Measures:
  • weight loss [ Time Frame: 12 weeks ]
    Body weight of participants in soy fiber group was decreased significantly over the study period compared with the baseline.


Secondary Outcome Measures:
  • serum levels of total cholesterol [ Time Frame: 12 weeks ]
    Serum levels of total cholesterol of participants in soy fiber group was decreased significantly over the study period compared with the baseline.

  • serum levels of low density lipoprotein cholesterol [ Time Frame: 12 weeks ]
    Serum levels of low density lipoprotein cholesterol of participants in soy fiber group was decreased significantly over the study period compared with the baseline.

  • body fat [ Time Frame: 12 weeks ]
    Body fat of participants in soy fiber group was lowered significantly at wk 12 than that of baseline.


Enrollment: 39
Study Start Date: March 2012
Study Completion Date: July 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: biscuits without soy fiber
biscuits without soy fiber
Experimental: biscuits supplemented with soy fiber
biscuits supplemented with soy fiber
Dietary Supplement: biscuits supplemented with soy fiber
Thirty nine overweight and obese college adults (19-39 y of age) were randomly assigned to consume control biscuits or biscuits supplemented with soy fiber for 12 wk (approximately 100g/d).

Detailed Description:
Thirty nine overweight and obese college adults (19-39 y of age) were randomly assigned to consume control biscuits or biscuits supplemented with soy fiber for 12 wk (approximately 100g/d). Information on body weight, body mass index, waist/hip circumference, blood pressure as well as measures of lipoprotein, glucose concentrations, and HbA1c was obtained at baseline, 8 and 12 wk after intervention. Body composition was also assessed at baseline and wk 12, respectively.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years to 39 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • BMI of 23-35 kg/m2

Exclusion Criteria:

  • Subjects taking any drugs, botanicals or nutraceutical known to influence body weight or blood pressure
  • significant history of eating disorders
  • strenuous exercise to lose weight
  • lipid-lowering medication
  • use of steroids and other agents that may influence lipid metabolism
  • hyperlipidemia
  • hyperglycemia
  • diabetes mellitus
  • cardiovascular disease
  • major systemic diseases
  • gastrointestinal problems
  • liver and renal failure
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01802840


Locations
China, Zhejiang
Zhejiang University
Hangzhou, Zhejiang, China, 310058
Sponsors and Collaborators
Zhejiang University
Investigators
Study Director: Duo Li, Prof. Zhejiang University